Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biopharmaceutical company developing important new therapies ...

The grant was approved by the Compensation Committee on March 16, 2025, pursuant to a delegation by the Board of Directors and was issued as an equity grant pursuant to Nasdaq Listing Rule 5635 (c) (4 ...

The approved inducement grant comes as Etsy targets a stickier app experience as part of a strategy to reverse an ongoing ...

The CMO Inducement Grant has an exercise price per share that is equal to the closing price of Viridian’s common stock on the CMO Grant Date. The CMO Inducement Grant will vest over a four-year ...

The grant was offered as material inducement to Zamansky’s employment as Amwell’s chief product and technology officer. The RSUs become vested as follows, subject to Zamansky’s continued ...

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics.

The stock option granted on November 5, 2024 has a ten-year term and an exercise price of $3.59 per share, which is equal to ...

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and ...

The grant was offered as material inducement to Zamansky’s employment as Amwell’s chief product and technology officer. The RSUs become vested as follows, subject to Zamansky’s continued employment ...

The new non-executive employee received an option to purchase 35,000 shares of Annexon common stock. The option carries a ten-year term and an exercise price per share equal to $2.60, which was the ...

The awards were granted as an inducement material to the employees entering into employment with Gossamer in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $ ...

The inducement equity awards were granted effective as of March 3, 2025 and consist of (i) a non-statutory stock option to purchase up to 48,000 shares of Ocular’s common stock at a per share exercise ...